Skip to content
Lower risk Drug recall · FDA · Published August 19, 2026

American Health Packaging Buprenorphine Tablets Recall: Label Mix-Up Hazard

American Health Packaging recalls 2mg Buprenorphine Sublingual Tablets (C-III) due to labeling mix-up. This may cause confusion with similar products. Check carton NDC 60687-481-21 for affected items.

🇺🇸 FDA recall #D-0840-2026DrugAmerican Health Packaging ›
✎ GovInfoNow plain-language explainer

American Health Packaging is recalling 2mg Buprenorphine Sublingual Tablets (C-III) because of a labeling mix-up. This could lead to confusion with similar products, potentially causing incorrect use. Read more at govinfonow.com/recall/1004693-american-health-packaging-buprenorphine-tablets-recall-label-mix-up-hazard.

Source Summary by GovInfoNow · govinfonow.com/recall/1004693-american-health-packaging-buprenorphine-tablets-recall-label-mix-up-hazard · Updated September 23, 2026 · FDA enforcement record: FDA #D-0840-2026

Cite this page

“American Health Packaging Buprenorphine Tablets Recall: Label Mix-Up Hazard.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/1004693-american-health-packaging-buprenorphine-tablets-recall-label-mix-up-hazard. Based on FDA recall #D-0840-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0840-2026%22&limit=1).

The Food and Drug Administration announced on Aug. 19, 2026, that American Health Packaging is voluntarily recalling Buprenorphine Sublingual Tablets due to a labeling mix-up hazard. Owners should contact the company for a refund.

How to tell if you have it

  • Brand: American Health Packaging
  • Product: Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only
  • Carton NDC#: 60687-481-21
  • Individual Dose NDC: 60687-481-11
  • Lot #: 1030023
  • Exp Date: 06/30/2027
  • Distributed by: American Health Packaging, Columbus, Ohio 43217
  • Distribution: US Nationwide
  • Units affected: 10,953 cartons

The hazard

The recall involves a labeling mix-up for the drug product. The FDA classified this as a Class III recall, indicating it is not likely to cause adverse health consequences but violates labeling regulations.

Context

GovInfoNow's records show American Health Packaging has 41 other recalls on record since July 23, 2012. Other recent recalls of similar products include American Regent Levocarnitine Injection Recall: Missing Label Hazard (April 16, 2026), Sun Pharmaceutical Perampanel 6mg Tablets Recall: Label Mix-Up Risk (June 17, 2026), and Par Health Buprenorphine Injection Recall: Crystallization Risk (June 12, 2026).

How to tell if you have this one

Check the carton label for NDC 60687-481-21. The product is a 2mg Buprenorphine Sublingual Tablet (C-III) with 30 tablets (3x10) and expires June 30, 2027.

  • Brand
    American Health Packaging
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Label

    Look for the carton NDC number 60687-481-21 on the product packaging.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “US Nationwide.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 21 days after the firm started it.

1. Firm started the recall: Aug 19, 202612. Published in FDA’s Enforcement Report: Sep 9, 202623. FDA classified it Class III: Sep 14, 202634. Added to GovInfoNow: Sep 23, 202642026
  1. Firm started the recall
  2. Published in FDA’s Enforcement Report
  3. FDA classified it Class III
  4. Added to GovInfoNow

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this product safe to use?

The recall is due to a labeling mix-up, not a safety issue. The product is safe to use if the correct label is present.

What should I do if I have the recalled product?

The recall does not require immediate action. Check the product label to confirm if it matches the NDC 60687-481-21. If unsure, contact your healthcare provider.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0840-2026 (August 19, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0840-2026 to see it in context.
  • Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA